 |
3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
|---|---|
| Trade Name | |
| Orphan Indication | Cystic fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2010-03-02 00:00:00 |
| Sponsor | Vertex Pharmaceuticals Inc.;130 Waverly Street;Cambridge, Massachusetts, 02139 |
Related Access Program